Pharmacokinetic parameter driven outcomes model predicts a reduction in bleeding events associated with BAY 81–8973 versus antihemophilic factor (recombinant) plasma/albumin-free method in a Chinese healthcare setting

Table 3 Scenario analyses of lower dosing

	Dosing 25 IU/kg (base case)	Dosing 20 IU/kg	Dosing 15 IU/kg
Costs
BAY 81–8973	¥16,930,390	¥13,703,193	¥10,487,104
rAHF-PFM	¥17,052,210	¥13,821,831	¥10,599,846
Incremental cost	-¥121,819	-¥118,638	-¥112,742
QALYs
BAY 81–8973	13.220	13.202^a	13.179^a
rAHF-PFM	13.167	13.151^a	13.132^a
Incremental QALYs	0.053	0.050	0.047
ICER	BAY 81–8973 is dominant (lower costs and higher QALY gain)

^aDerived using the annual bleeding rate of 25 IU/kg
ICER incremental cost-effectiveness ratio, rAHF-PFM: antihemophilic factor (recombinant) plasma/albumin-free method; QALYs: quality-adjusted life years

ISSN: 1471-2288